Search Results for "Low Dose Etanercept In Ank Spond"
Original Source: Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease.
This study aims to explore the effectiveness of low dose of etanercept (ETN) in patients with ankylosing spondylitis (AS) who achieve a good control of their disease in daily clinical practice. This is a case series of AS patients treated with ETN. According to the judgment of the treating rheumatologist and patient's preferences, a dose reduction was done in those patients who achieved a good control of their disease defined by Bath ankylosing spondylitis disease activity index (BASDAI)
Matching Channels
Thimerosal is a mercury-based preservative that has been used for decades in the United States in multi-dose vials (vials containing more than one dose) of some vaccines to prevent the growth of ger...
Technical Background Tumor necrosis factor (TNF) is a substance made by your body's immune system. People with inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic a...
Kadcyla (ado-trastuzumab emtansine)
Kadcyla™ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab)...
Prostate cancer is the most common cancer in men in the UK; affecting 250,000 men. Risk factors for prostate cancer include age (average age at diagnosis is 70), a family history and a Caribbean or...
Crohns Disease is a chronic inflammatory disease, affecting the whole of the alimentary tract from mouth to anus, and all layers of the gut wall. The most commonly affected sites are the terminal il...
Matching News
Low-Dose Etanercept May Not Stop RA Damage
Low-dose etanercept produces clinical control similar to that from standard dosing but does not prevent radiographic progression of joint damage. Medscape Medical News
Etanercept users with stable disease activity 'may safely reduce dose'
Rheumatoid arthritis patients who use a drug called etanercept (brand name Enbrel) may safely reduce the dose if their disease has responded well to treatment, a new study in the Lancet medical journa...
Conventional or reduced doses of etanercept with methotrexate in patients with moderately active rheumatoid arthritis more effectively maintain low disease activity than does methotrexate alone after...
Methotrexate and Etanercept for Plaque Psoriasis
This study evaluated etanercept plus methotrexate vs. etanercept monotherapy in patients with moderate to severe plaque psoriasis. The British Journal of Dermatology
Short/long-term analyses deem etanercept safe for psoriasis
(HealthDay) -- Etanercept treatment is well tolerated for psoriasis, with no indication of dose-related or cumulative toxicity in short- or long-term analyses, according to a study published in the Au...
Etanercept, adalimumab equal in RA, unless antibodies develop
NEW YORK (Reuters Health) - Etanercept and adalimumab appear similarly effective against rheumatoid arthritis (RA) in patients who haven't been treated with anti-TNF agents, Dutch researchers say.
India's Cipla launches etanercept biosimilar
MUMBAI, April 17 (Reuters) - Indian drugmaker Cipla Ltd said on Wednesday it has launched etanercept biosimilar in India under the brand name Etacept.
Etanercept no better than prednisone for COPD exacerbations
Results from a randomized, double-blind, controlled trial suggest that the tumor necrosis factor α antagonist etanercept is no more effective than standard therapy with prednisone for the treatment o...
Matching PubMed Articles
We report a 16-year-old female case of intractable adult-onset Still's disease accompanied by macrophage activation syndrome, who went into full remission after switching from infliximab to etanercept...
Abstract Objective: To describe dosing patterns of etanercept, adalimumab, and infliximab in rheumatoid arthritis (RA) patients in US managed care. Methods: This retrospective analysis included adult...
Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients.
Recent papers highlight the role of dysregulated expression of antimicrobial peptides and proteins (AMPs) in the pathogenesis of psoriasis. Etanercept, a blocker of the pro-inflammatory cytokine tumou...
A 41-year-old woman presented with continuous fever, and her laboratory data suggested the recrudescence of systemic lupus erythematosus. She was treated with 60 mg/day prednisolone. With a dose redu...
Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
BACKGROUND: In two previous phase 3 studies, up to 60 weeks of etanercept therapy significantly improved the symptoms of psoriasis and was well tolerated. OBJECTIVE: To evaluate the long-term safety o...
